< Back to previous page
Researcher
Steven Simoens
- Disciplines:Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Jul 2013 → Today
Projects
1 - 10 of 22
- How to create sustainable market access to advanced therapies?From1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Health Economic Evaluations of Preventive Policies in Flanders (HELPPFL)From22 Nov 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Exploring the market access of advanced therapy medicinal products (ATMPs)From17 Oct 2022 → 9 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Exploring the market environment of biologics including biosimilar medicinesFrom20 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market SustainabilityFrom16 Oct 2019 → 13 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- A Belgian policy framework for best-value biological medicinesFrom3 Sep 2019 → 18 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Framework for value driven market access of gene therapyFrom1 Sep 2019 → 23 Oct 2020Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 428
- Drug pricing and transparency in Europe and the United States: what is it and how does it work?(2024)
Authors: Steven Simoens
- An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.(2024)
Authors: Walter Van Dyck, Steven Simoens
Pages: 21 - 34 - Cost-Utility of an Exercise Referral Scheme Versus Doing Nothing in Flemish Adults: Exploring the Impact of Key Assumptions(2024)
Authors: Steven Simoens
- Unlocking Biosimilar Benefits: An Exploration of Barriers to Biosimilar Adoption, Value Assessment and Market Sustainability(2023)
Authors: Teresa Barcina Lacosta, Steven Simoens, Isabelle Huys
- Reply to Standaert, B. Comment on "Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium"(2023)
Authors: Steven Simoens
- Not one, but many: developing a multi-indication pricing model for medicines in Belgium(2023)
Authors: Steven Simoens
- A Belgian policy framework for best-value biological medicines(2023)
Authors: Yannick Vandenplas, Isabelle Huys, Steven Simoens, Arnold Vulto
- An international comparative analysis and roadmap to sustainable biosimilar markets(2023)
Authors: Steven Simoens
- A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report(2023)
Authors: Steven Simoens
Pages: 1137 - 1144 - The impact of policy interventions to promote the uptake of biosimilar medicines in Belgium: a nationwide interrupted time series analysis(2023)
Authors: Yannick Vandenplas, Steven Simoens, Arnold Vulto, Isabelle Huys